- Home
- ICCM vs RDHL Comparison
ICCM vs RDHL Comparison
Compare ICCM & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | RDHL |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.7M |
| IPO Year | 2013 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ICCM | RDHL |
|---|---|---|
| Price | $0.77 | $0.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.67 | N/A |
| AVG Volume (30 Days) | ★ 118.4K | 90.7K |
| Earning Date | 11-23-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.11 | $17,592.31 |
| Revenue Next Year | $104.97 | $25.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.38 |
| 52 Week High | $9.54 | $1.60 |
Technical Indicators
Market Signals| Indicator | ICCM | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 36.35 |
| Support Level | $0.22 | N/A |
| Resistance Level | $2.50 | $0.47 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 25.02 | 9.12 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.